PROFILBARU.COM

Naftifine
Clinical data
Trade names	Exoderil, Naftin
AHFS/Drugs.com	Monograph
MedlinePlus	a688020
ATC code	D01AE22 (WHO) ;
Identifiers
	IUPAC name (2E)-N-methyl-N-(1-naphthylmethyl)-3-phenylprop-2-en-1-amine;
CAS Number	65472-88-0 ;
PubChem CID	47641;
DrugBank	DB00735 ;
ChemSpider	66071 ;
UNII	4FB1TON47A;
ChEBI	CHEBI:7451 ;
ChEMBL	ChEMBL626 ;
CompTox Dashboard (EPA)	DTXSID6048545 ;
Chemical and physical data
Formula	C21H21N
Molar mass	287.406 g·mol−1
	(what is this?) (verify)

Naftifine hydrochloride (brand names include Exoderil and Naftin) is an allylamine antifungal drug for the topical treatment of tinea pedis, tinea cruris, and tinea corporis (topical fungal infections).

Naftifine was invented at the Sandoz Research Institute in Vienna, Austria. It was the first successful antifungal medication of the allylamine class.^[1]

Naftifine has triple action: antifungal, antibacterial, and anti-inflammatory. Its fungistatic activity is believed to be based on inhibition of the squalene-2,3-epoxidase enzyme, which in turn results in the shortage of ergosterol required for the formation of fungal cell membranes. With some fungal species, there is also fungicidal activity from a resulting accumulation of squalenes, leading to damage of the fungal cell membranes, including at the endoplasmatic reticulum.^[1]^[2]^[3] Naftifine shows mostly fungicidal activity toward dermatophytes and molds, and mostly fungistatic activity toward yeasts. It is also effective as an antibacterial agent in treating pyoderma. ^{[citation needed]}

Naftifine is almost completely metabolized in the human body, with a half-life of 2–3 days.^[3] The metabolites do not have antifungal activity, and are excreted within urine and feces.^[4]

References

^ ^a ^b Mühlbacher JM (1991). "Naftifine: a topical allylamine antifungal agent". Clinics in Dermatology. 9 (4): 479–85. doi:10.1016/0738-081x(91)90076-w. PMID 1822408.
^ Robertson DB, Maibach HI (2009). "Dermatologic Pharmacology.". In Katzung BG, Masters SB, Trevor AJ (eds.). Basic and Clinical Pharmacology (11th ed.). New York: McGraw Hill Medical. ISBN 978-0-07-160406-2.
^ ^a ^b Naftifine Hydrochloride. Micromedex DRUGDEX Drug Point (Report). 18 February 2010..
^ Sebela Pharmaceuticals Inc. (April 2018). "NAFTIN®- naftifine hydrochloride gel" (PDF). www.accessdata.fda.gov. Retrieved 2022-07-03.